Turkish Scientist Rahmi Öklü’s Company Obsidio to Receive 3 Million Dollars for Clinical Studies of Its Biomaterial
Prof. Dr. Rahmi Oklu is known for his work focusing on patient-inspired engineering to develop medical devices. He is one of the world's leading figures in interventional radiology.

From the US Mayo Clinic's Department of Vascular and Interventional Radiology, Prof. Dr. Rahmi Öklü's medical materials development company Obsidio, their developed embolizing (vessel-blocking)
The company, whose Founder and Chief Medical Officer is Rahmi Öklü, will also be eligible for a Phase I Small Business Innovation Research (SBIR) grant from the National Science Foundation (NSF). This will help bring the research into clinical practice and to patients.
Minimally invasive interventions are one of the cornerstones of modern medicine. In the recent past, as minimally invasive methods have begun to be preferred over complex open surgical methods, generally offering better outcomes, lower costs and fewer complications, their applications and research have also expanded.
Blood vessels are a common route into the body that permits minimally invasive interventions. An endovascular approach can provide access to almost all organs.
Through an endovascular approach, embolic (blocking) agents can be deposited within blood vessels to occlude them. In short, this procedure, called embolization, can reduce blood flow to that part of the body. Embolization offers advantages in many situations. Applications include targeting a tumor and blocking the blood vessels feeding it, controlling sudden life-threatening bleeding, eliminating abnormal connections between vessels and treating aneurysms.
Is there an ideal embolic material?
One of the important questions raised by the wide range of embolization applications is whether an ideal embolic material exists. In the early years, when pieces of muscle, blood clots and stainless steel pellets were used as embolic agents, natural substances were found to fail at embolization. As a result, researchers and doctors turned to developing new embolic agents. Today there is still no "one-size-fits-all solution," and all available materials have shortcomings as well as advantages.
An ideal embolic material should offer the following;
- Biocompatibility
- Ease of delivery
- Resistance to fragmentation / migration
- Biodegradability (depending on the application)
- Visibility and traceability with common imaging methods such as fluoroscopy, magnetic resonance imaging (MRI), computed tomography (CT) or ultrasound
- The ability to act as a therapeutic delivery vehicle (for example, for an anticancer drug).
Since the vessels to be treated range from 1-2 cm to 5-10 micrometers in diameter, the embolic agent is critically important. At this point, the biomaterial developed in 2016 by Turkish doctor Prof. Dr. Rahmi Öklü and his team at the Mayo Clinic in the United States targeted an important need for embolic agents. The biomaterial developed by the team has a high degree of effectiveness in permanently occluding blood vessels. Over time, Obsidio's material replaces natural tissue and leaves behind no foreign material that becomes inflamed.
Obsidio announced that it had completed a funding round with venture capital firm Good Growth Capital on 21 August 2019 for its vessel-blocking material made of gelatin and silicate nanoparticles. On 6 August 2020, Good Growth Capital announced that it would provide Obsidio with 3 million dollars in support for Phase 1 studies. In addition, the National Science Foundation (NSF) awarded Obsidio a Phase I Small Business Innovation Research (SBIR) grant. Obsidio plans to use the proceeds for clinical development of its embolic hydrogel material.
Obsidio's embolization material has a wide range of applications. It can be injected through many different catheters and is compatible with most imaging techniques. It also eliminates costs associated with embolic devices already on the market. This technology offers an elegant solution for managing embolization, a serious and difficult-to-treat problem.
In conclusion, we see this development as an important milestone in the history of embolic agents, which have continued to develop for more than a century. We congratulate Turkish scientist Rahmi Öklü and his team on their successful applications and eagerly await the clinical tests and results.
Who is Rahmi Oklu? (Brief academic CV)
Rahmi Oklu is a Professor and Chair of Vascular and Interventional Radiology and Director of the Minimally Invasive Therapeutics Laboratory at the Mayo Clinic in the United States. He graduated from medical school at Northwestern University, earned a master's degree from Yale University and a doctorate in biochemistry from Cambridge University. He completed his surgical and radiology training at Columbia University's NY Presbyterian Hospital. He worked in vascular and interventional radiology at Massachusetts General Hospital, Harvard Medical School. He is known for his work focusing on patient-inspired engineering to develop medical devices. He is one of the world's leading figures in interventional radiology.
Below, Prof. Dr. Rahmi Öklü and his team, consisting mostly of Turkish physicians

Sources
https://www.prnewswire.com/news-releases/obsidio-inc-closes-3-million-round-receives-grant-from-the-national-science-foundation-and-welcomes-new-board-member-301107363.html
2. Avery RK, Albadawi H, Akbari M, Oklu R, et al. An injectable shear-thinning biomaterial for endovascular embolization.
Science Translational Medicine. 16 November 2016
3. Obsidio Raises Seed Round led by Good Growth Capital to Develop Universal Gel Embolic Material.
https://www.ktvn.com - 21 August 2019.
4. Jingjie Hu, Hassan Albadawi, Brian W. Chong, Amy R. Deipolyi, Rahul A. Sheth, Ali Khademhosseini, Rahmi Oklu.
Advances in Biomaterials and Technologies for Vascular Embolization.
Advanced Materials, 6 June 2019.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.